What is Zacks Research’s Estimate for Exelixis Q4 Earnings?

Exelixis, Inc. (NASDAQ:EXEL) – Equities research analysts at Zacks Research boosted their Q4 2024 earnings per share (EPS) estimates for Exelixis in a report issued on Monday, December 16th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings of $0.37 per share for the quarter, up from their prior forecast of $0.36. The consensus estimate for Exelixis’ current full-year earnings is $1.69 per share. Zacks Research also issued estimates for Exelixis’ Q4 2025 earnings at $0.45 EPS, FY2025 earnings at $1.57 EPS, Q1 2026 earnings at $0.43 EPS, Q2 2026 earnings at $0.49 EPS and FY2026 earnings at $2.14 EPS.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. The firm had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 EPS.

Other equities research analysts have also issued reports about the company. Truist Financial boosted their price objective on Exelixis from $33.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. TD Cowen upped their target price on Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a report on Monday, October 21st. Stephens upped their price objective on shares of Exelixis from $23.00 to $29.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Exelixis in a research note on Wednesday, September 18th. Finally, Piper Sandler lifted their price target on shares of Exelixis from $33.00 to $36.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.44.

Exelixis Stock Down 1.2 %

EXEL stock opened at $33.29 on Thursday. Exelixis has a 52 week low of $19.20 and a 52 week high of $36.97. The firm has a 50-day simple moving average of $33.36 and a 200-day simple moving average of $27.47. The stock has a market capitalization of $9.51 billion, a P/E ratio of 21.34, a P/E/G ratio of 0.89 and a beta of 0.52.

Insider Activity at Exelixis

In other news, EVP Dana Aftab sold 96,986 shares of Exelixis stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total value of $3,394,510.00. Following the completion of the transaction, the executive vice president now owns 498,945 shares in the company, valued at approximately $17,463,075. This trade represents a 16.27 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director George Poste sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $34.00, for a total transaction of $1,020,000.00. Following the sale, the director now owns 169,020 shares in the company, valued at $5,746,680. The trade was a 15.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 339,736 shares of company stock worth $11,508,610. Corporate insiders own 2.85% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in EXEL. Covestor Ltd raised its holdings in shares of Exelixis by 5.7% in the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 341 shares in the last quarter. Resonant Capital Advisors LLC lifted its holdings in Exelixis by 3.6% during the 2nd quarter. Resonant Capital Advisors LLC now owns 13,746 shares of the biotechnology company’s stock worth $309,000 after buying an additional 477 shares during the last quarter. Cornercap Investment Counsel Inc. boosted its position in shares of Exelixis by 1.1% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 50,497 shares of the biotechnology company’s stock worth $1,135,000 after acquiring an additional 539 shares in the last quarter. Creative Planning increased its holdings in shares of Exelixis by 0.8% in the 2nd quarter. Creative Planning now owns 71,700 shares of the biotechnology company’s stock valued at $1,611,000 after acquiring an additional 548 shares during the last quarter. Finally, Advisors Asset Management Inc. raised its position in shares of Exelixis by 3.2% during the 3rd quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock worth $515,000 after acquiring an additional 609 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.